Alobresib

Overview

Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc . Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-109050
• CAS No.: 1637771-14-2
• Molecular Formula: C26H23N5O2
• Molecular Weight: 437.49
• Purity: 98.04%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.75 mM); Clear solution
• Availability: In-stock

Source

Original product source